For decades, millions of women diagnosed with Polycystic Ovary Syndrome said the name never fully reflected what they were experiencing. Now, after years of global debate among researchers and patient advocates, the condition has officially been renamed.
PCOS has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) after a 14-year global effort involving researchers, doctors, and patient groups.
Professor Helena Teede, Director of Monash University’s Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health, led the name change process after spending decades researching the condition.
The new name was carefully selected to reflect the fact that the condition affects several interconnected systems in the body, rather than being limited to the ovaries alone.
Why Polyendocrine?
The term “polyendocrine” comes from “poly,” meaning multiple, and “Endocrine” refers to the body’s hormone-producing system
This part of the name recognises that the condition involves disruptions in multiple hormonal pathways simultaneously. In people living with PCOS (now PMOS), hormones that regulate reproduction, metabolism, stress response, and insulin function can become imbalanced.
For example, many patients experience elevated levels of androgens, often referred to as “male hormones,” although they are naturally present in all bodies. High androgen levels can contribute to excess facial or body hair, acne, hair thinning or hair loss, and irregular ovulation.
The condition can also interfere with hormones that regulate menstrual cycles, including luteinising hormone (LH), follicle-stimulating hormone (FSH), estrogen, and progesterone. Because several hormonal systems are involved simultaneously, experts felt the previous name, which focused mainly on ovarian cysts, failed to capture the complexity of the disorder.
The use of “polyendocrine” therefore acknowledges PMOS as a broader hormonal syndrome affecting the entire endocrine system.
Why Metabolic?
The inclusion of “metabolic” highlights one of the most important but often overlooked aspects of the condition: its connection to metabolism and long-term health risks.
Many people with PCOS (now PMOS) experience insulin resistance, a condition where the body’s cells do not respond properly to insulin. As a result, the pancreas produces more insulin to compensate.
High insulin levels can worsen hormonal imbalance and stimulate increased androgen production. This metabolic dysfunction can contribute to a wide range of health complications.
Many people living with PCOS (now PMOS) experience weight gain or find it unusually difficult to lose weight, even with lifestyle changes. The condition is also associated with increased abdominal fat, which experts say is closely linked to hormonal imbalance and insulin resistance.
In addition, patients may develop high cholesterol levels and elevated blood sugar, both of which can increase the risk of developing Type 2 diabetes over time.
Medical experts also warn that these metabolic issues may raise the likelihood of cardiovascular diseases, including high blood pressure and heart-related complications, particularly when the condition is left unmanaged for long periods.
Doctors say this aspect of the syndrome has historically been underemphasised, even though metabolic complications can have serious long-term consequences if unmanaged.
The addition of “metabolic” is intended to encourage healthcare providers to move beyond treating only fertility or menstrual symptoms and instead monitor patients’ overall health, including blood sugar, heart health, and nutrition.
Why retain Ovarian syndrome?
Although the condition affects much more than the ovaries, experts decided to retain the word “ovarian” because reproductive symptoms remain central to the syndrome.
PCOS (now PMOS) commonly affects ovulation, the process by which the ovaries release eggs during the menstrual cycle. This can lead to irregular periods, missed periods, difficulty conceiving, fertility issues, and challenges.
Some patients may also develop enlarged ovaries or follicles visible on ultrasound scans, although not everyone with the condition has these features.
Keeping “ovarian” in the name acknowledges that reproductive health remains an important part of the condition while balancing it with the newly recognised hormonal and metabolic dimensions.
Importantly, the renaming does not mean the condition itself has changed. The diagnostic criteria, symptoms, and treatments remain largely the same for now. Doctors will still diagnose patients based on hormonal symptoms, ovulation issues, and ultrasound findings, as needed.
Conclusion
Overall, experts say the new name represents a shift in medical understanding. Rather than viewing the condition primarily as an ovarian disorder, PMOS is now understood as a complex, multisystem syndrome involving reproductive health, metabolism, and hormones.